HR 890 · in committee · significant
Stopping Pharma’s Ripoffs and Drug Savings For All Act
- healthcare
What this bill does
- The bill requires drug patent owners to prove each patent covers a distinct invention or lose all patents when the first one expires.
- Pharmaceutical companies and generic drug manufacturers are affected by new patent validity standards.
- The USPTO must review and reform its drug patent examination procedures to prevent duplicate patents.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How would requiring pharmaceutical companies to prove each patent covers a distinct invention affect the timeline and cost of bringing new drugs to market?
- 02
What evidence exists that duplicate drug patents currently delay generic drug entry and raise medication costs for consumers?
- 03
Which stakeholders—patients, generic manufacturers, or brand-name companies—would face the greatest burden under the USPTO's new patent examination standards?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · D-NY-18
Patrick Ryan
Citizen cosponsors
0
In Congress
0/ 435
House Reps cosponsoring
Introduced 2025-01-31
Legislative timeline
2025-01-31 · house · IntroReferral
Referred to the House Committee on the Judiciary.
2025-01-31 · IntroReferral
Introduced in House
2025-01-31 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.